Court Rules in Eurofins Viracor’s favor in Patent Infringement Case

LEE’S SUMMIT, Mo.--(BUSINESS WIRE)--Regulatory News:

The United States District Court for District of Delaware has ruled that the patent asserted in CareDx’s patent infringement case against Eurofins Viracor is invalid. Eurofins Viracor is very pleased that the Court has agreed with its arguments and issued judgment in Eurofins Viracor’s favor in this challenge to Eurofins’ critically important diagnostic tools to manage organ rejection risk.

Eurofins Viracor’s offerings include Viracor TRAC^® Kidney dd-cfDNA, Viracor TRAC^® Heart dd-cfDNA and Viracor TRAC^® Lung dd-cfDNA. In related innovation for transplant patients earlier this week, Eurofins Viracor’s affiliate, Transplant Genomics, Inc. (“TGI”), launched OmniGraf™, which combines the TruGraf® blood gene expression test and Viracor TRAC® donor-derived cell-free DNA assays. For renal transplant recipients, OmniGraf™ Kidney represents the first diagnostic tool that combines cell free DNA and gene expression data. When combined with TGI’s proprietary technology and machine learning, the test offers patients and clinicians an early and accurate assessment of kidney transplant rejection.

OmniGraf™ is a trademark of Transplant Genomics, Inc.

TruGraf® is a registered trademark of Transplant Genomics, Inc.

Viracor TRAC® is a registered trademark of Eurofins Viracor, LLC

Notes to Editors:

For more information, please visit https://www.eurofins-viracor.com/clinical/

About Viracor

With over 30 years of specialised expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Viracor Eurofins is committed to delivering results to medical professionals, transplant teams, reference laboratories and biopharmaceutical companies faster, when it matters most. Eurofins Viracor is passionate about delivering value to its clients by providing timely, actionable information, never losing sight of the connection between the testing it performs and the patients it ultimately serves.

Eurofins Viracor is a subsidiary of Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit https://www.eurofins.com/ and https://www.eurofins-viracor.com/.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agroscience Contract Research Organisation services. Eurofins is one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in the support of clinical studies, as well as having an emerging global presence in Contract Development and Manufacturing Organisations. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With 55,000 staff across a decentralised and entrepreneurial network of 900 laboratories in over 50 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group’s objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.

In 2020, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 25 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments, travel and events during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.

Sally Maysent
Director of Marketing
Email: SallyMaysent@Eurofins-Viracor.com

Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@eurofins.com